Navegando por Palavras-chave "thalidomide"

Agora exibindo 1 - 3 de 3
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Advances in the treatment of multiple myeloma: the role of thalidomide
    (Taylor & Francis Ltd, 2003-01-01) Ribas, Christian [UNIFESP]; Colleoni, Gisele Wally Braga [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Multiple myeloma (MM) accounts for 1% of all malignancies and 10% of malignant hematological neoplasms. in spite of high-dose therapy with stem cell rescue, relapse and disease resistance are common events in the course of the disease. Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation. Here, we review the underlying concepts and current clinical data regarding Thal in the treatment of MM.
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma
    (Amer Roentgen Ray Soc, 2007-08-01) Faria, Silvana C.; Ng, Chaan S.; Hess, Kenneth R.; Phongkitkarun, Sith; Szejnfeld, Jacob [UNIFESP]; Daliani, Danai; Charnsangavej, Chusilp; Univ Texas; Universidade Federal de São Paulo (UNIFESP)
    OBJECTIVE. Our objective was to use functional CT to evaluate the effects of thalidomide in patients with metastatic renal cell carcinoma.SUBJECTS and METHODS. Patients with proven metastatic renal cell carcinoma were examined prospectively with functional CT. Functional CT studies (cine mode, 4 x 5 mm) were performed through the tumor after IV administration of a bolus of contrast material before and every 12 weeks after treatment with thalidomide. Quantitative values for blood flow, blood volume, mean transit time, and permeability-surface area product were calculated with commercial software. the average difference in percentage change in functional CT parameters from pretreatment to 12 and 24 weeks after treatment and the median difference in percentage change in functional CT parameters between response groups were assessed. We also tested whether percentage changes in functional CT parameters 12 weeks after treatment correlated with time to progression of disease and size of the perfused lesion.RESULTS. Sixteen patients with a total of 23 tumors underwent at least one follow-up functional CT examination. Blood flow, blood volume, and permeability-surface area product decreased significantly 12 weeks (-18%, p = 0.0039; -15%, p = 0.0350; -24%, p = 0.0010) and 24 weeks (-28%, p = 0.017; -19%, p = 0.0300; -25%, p = 0.0031) after treatment with thalidomide. Time to progression correlated significantly with percentage change in blood flow (r = -0.34; p = 0.040) and permeability-surface area product (r = -0.36, p = 0.023) at 12 weeks. Responders had a significantly larger decrease in blood flow 12 weeks after treatment than did nonresponders (-29% vs -6%; p = 0.032). We also found a significant correlation between decrease in size of the perfused lesion and percentage decrease in blood flow 12 weeks after treatment (r = 0.50; p = 0.019).CONCLUSION. Changes in functional CT parameters 12 weeks after treatment may be useful for monitoring the effects of thalidomide and predicting treatment outcome among patients with metastatic renal cell carcinoma. Further study with a larger clinical trial is needed.
  • Imagem de Miniatura
    Item
    Acesso aberto (Open Access)
    Standardization of a method to study angiogenesis in a mouse model
    (Academia Brasileira de Ciências, 2013-01-01) Feder, David; Perrazo, Fabio F.; Pereira, Edimar Cristiano [UNIFESP]; Forsait, Silvana; Feder, Cecilia K.r.; Junqueira, Paulo E.b.; Junqueira, Virginia Berlanga Campos [UNIFESP]; Azzalis, Ligia Ajaime [UNIFESP]; Fonseca, Fernando Luiz Affonso [UNIFESP]; Faculdade de Medicina do ABC Departamento de Morfologia e Fisiologia Disciplina de Farmacologia; Universidade Federal de São Paulo (UNIFESP)
    In the adult organism, angiogenesis is restricted to a few physiological conditions. On the other hand, uncontrolled angiogenesis have often been associated to angiogenesis-dependent pathologies. A variety of animal models have been described to provide more quantitative analysis of in vivo angiogenesis and to characterize pro- and antiangiogenic molecules. However, it is still necessary to establish a quantitative, reproducible and specific method for studies of angiogenesis factors and inhibitors. This work aimed to standardize a method for the study of angiogenesis and to investigate the effects of thalidomide on angiogenesis. Sponges of 0.5 x 0.5 x 0.5 cm were implanted in the back of mice groups, control and experimental (thalidomide 200 mg/K/day by gavage). After seven days, the sponges were removed. The dosage of hemoglobin in sponge and in circulation was performed and the ratio between the values was tested using nonparametric Mann-Whitney test. Results have shown that sponge-induced angiogenesis quantitated by ratio between hemoglobin content in serum and in sponge is a helpful model for in vivo studies on angiogenesis. Moreover, it was observed that sponge-induced angiogenesis can be suppressed by thalidomide, corroborating to the validity of the standardized method.